4/19
08:03 am
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
High
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
4/18
03:45 pm
ocul
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder [Yahoo! Finance]
Low
Report
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder [Yahoo! Finance]
4/18
07:23 am
ocul
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy [Yahoo! Finance]
High
Report
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy [Yahoo! Finance]
4/18
07:00 am
ocul
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
High
Report
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
4/16
05:03 pm
ocul
ENPH, OCUL and ITCI are among after hour movers [Seeking Alpha]
Medium
Report
ENPH, OCUL and ITCI are among after hour movers [Seeking Alpha]
4/16
11:15 am
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $24.00 price target on the stock.
Low
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $24.00 price target on the stock.
4/16
07:19 am
ocul
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders [Yahoo! Finance]
Low
Report
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders [Yahoo! Finance]
4/16
07:00 am
ocul
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Low
Report
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
4/15
07:10 am
ocul
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO [Yahoo! Finance]
Medium
Report
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO [Yahoo! Finance]
4/15
07:00 am
ocul
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Medium
Report
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
4/9
07:39 am
ocul
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics [Yahoo! Finance]
Low
Report
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics [Yahoo! Finance]
4/9
07:30 am
ocul
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
Low
Report
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
4/6
10:03 am
ocul
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting [Yahoo! Finance]
4/6
10:00 am
ocul
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Medium
Report
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
4/5
11:02 pm
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/26
07:42 am
ocul
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) [Yahoo! Finance]
Low
Report
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery) [Yahoo! Finance]
3/26
07:30 am
ocul
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
Low
Report
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
3/25
05:18 pm
ocul
WPRT, FIVN and FATE are among after hour movers [Seeking Alpha]
Low
Report
WPRT, FIVN and FATE are among after hour movers [Seeking Alpha]
3/25
04:30 am
ocul
Ocular Inflammation Treatment Market InsightAce Exclusive Report 2024-2031 [Yahoo! Finance]
Medium
Report
Ocular Inflammation Treatment Market InsightAce Exclusive Report 2024-2031 [Yahoo! Finance]
3/19
04:24 pm
ocul
Ocular Therapeutics' Impressive Surge: A Strategic Insight [Seeking Alpha]
Low
Report
Ocular Therapeutics' Impressive Surge: A Strategic Insight [Seeking Alpha]
3/18
02:14 am
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/11
07:01 pm
ocul
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
3/11
04:27 pm
ocul
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
Low
Report
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
3/11
04:05 pm
ocul
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
Medium
Report
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
3/10
01:01 am
ocul
Ocular Therapeutix, Inc. (NASDAQ: OCUL) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Ocular Therapeutix, Inc. (NASDAQ: OCUL) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.